Market Forecast by Countries (Germany, United Kingdom, France, Italy, Russia, Spain, Rest of Europe), By Product (Insulin, Drug Class), By Patient Population (Pediatric, Adult, Geriatric), By Route of Administration (Insulin syringe/ Insulin pen, Insulin pump, Intravenous infusion, Oral, Others) And Competitive Landscape
Product Code: ETC078351 | Publication Date: Jan 2023 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 200 | No. of Figures: 90 | No. of Tables: 30 |
The Europe Antidiabetics Market is projected to grow efficiently over the forecast period and there are many factors contributing to the growth of the sector. The sector plays an essential role in the country and will remain an essential sector.
According to 6Wresearch, the Europe Antidiabetics Market size is expected to grow during 2023-2029. Diabetes is a rising health concern not just in the Europe but across the world and it is impacting millions of individuals across the globe. The demand for antidiabet5ic products and treatments has skyrocketed, which is leading to a growth in this sector. The country has the second biggest market for antidiabetics and it is anticipated to grow more at a faster pace. The growing prevalence of diabetes is the key factor driving the sector growth. Other factors that are driving the market are Rising sedentary lifestyle and rising prevalence of obesity.
The high cost of diabetes treatment and product is one key factor constraining the growth of the sector. The market will overcome these challenges in the years to come since the Europe Antidiabetics Market share will continue rising. The sector is gradually becoming one of the most significant sectors in the region and one of the major reasons behind it is that this sector is associated with healthcare sector. Insulin is the most common type of antidiabetic in the region. Sulfonylureas, thiazolidinediones (TZDs), and metformin are other popular types of antidiabetics available in the market. The demand for insulin is rising at a faster pace. The competition in this sector is high and it is anticipated to become more intense in the years to come. The opportunities in the sector has been rising and this is one of the major reasons the competition in the sector is constantly rising.
The demand for antidiabetics products and treatments decreased at a faster pace during the coronavirus pandemic owing to the fact that the diabetes patients cancelled and postponed their treatments owing to the severe coronavirus conditions in the region. Healthcare facilities were busy treating and meeting the needs of patients dealing with COVID-19, which affected the antidiabetics market growth. The supply chain also impacted negatively owing to the lockdown imposed in the continent. The sector is now rising and it will keep rising in the years to come. The growing prevalence of diabetes is the key factor driving the sector growth.
On the basis of nations, the Antidiabetics Market in Europe is divided into Germany, United Kingdom, France, Italy, Russia, Spain, and Rest Of Europe. Out of these, the France is anticipated to be the largest market for antidiabetics.
On the basis of product, the Europe Antidiabetics Industry is divided into Insulin, and Drug Class. All these product segments are rising in the sector.
On the basis of patient population, the sector is divided into Pediatric, Adult, and Geriatric. Among these, the Geriatric segment is likely to grow.
On the basis of route of administration, the market is divided into Insulin Syringe/ Insulin Pen, Insulin Pump, Intravenous Infusion, Oral, and Others. Among these, the insulin segment will account for the largest share.
The report offers a comprehensive study of the subsequent market segments:
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Europe Antidiabetics Market Overview |
3.1 Europe Regional Macro Economic Indicators |
3.2 Europe Antidiabetics Market Revenues & Volume, 2022 & 2029F |
3.3 Europe Antidiabetics Market - Industry Life Cycle |
3.4 Europe Antidiabetics Market - Porter's Five Forces |
3.5 Europe Antidiabetics Market Revenues & Volume Share, By Countries, 2022 & 2029F |
3.6 Europe Antidiabetics Market Revenues & Volume Share, By Product, 2022 & 2029F |
3.7 Europe Antidiabetics Market Revenues & Volume Share, By Patient Population, 2022 & 2029F |
3.8 Europe Antidiabetics Market Revenues & Volume Share, By Route of Administration, 2022 & 2029F |
4 Europe Antidiabetics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Europe Antidiabetics Market Trends |
6 Europe Antidiabetics Market, 2019 - 2029 |
6.1 Europe Antidiabetics Market, Revenues & Volume, By Product, 2019 - 2029 |
6.2 Europe Antidiabetics Market, Revenues & Volume, By Patient Population, 2019 - 2029 |
6.3 Europe Antidiabetics Market, Revenues & Volume, By Route of Administration, 2019 - 2029 |
7 Germany Antidiabetics Market, 2019 - 2029 |
7.1 Germany Antidiabetics Market, Revenues & Volume, By Product, 2019 - 2029 |
7.2 Germany Antidiabetics Market, Revenues & Volume, By Patient Population, 2019 - 2029 |
7.3 Germany Antidiabetics Market, Revenues & Volume, By Route of Administration, 2019 - 2029 |
8 United Kingdom Antidiabetics Market, 2019 - 2029 |
8.1 United Kingdom Antidiabetics Market, Revenues & Volume, By Product, 2019 - 2029 |
8.2 United Kingdom Antidiabetics Market, Revenues & Volume, By Patient Population, 2019 - 2029 |
8.3 United Kingdom Antidiabetics Market, Revenues & Volume, By Route of Administration, 2019 - 2029 |
9 France Antidiabetics Market, 2019 - 2029 |
9.1 France Antidiabetics Market, Revenues & Volume, By Product, 2019 - 2029 |
9.2 France Antidiabetics Market, Revenues & Volume, By Patient Population, 2019 - 2029 |
9.3 France Antidiabetics Market, Revenues & Volume, By Route of Administration, 2019 - 2029 |
10 Italy Antidiabetics Market, 2019 - 2029 |
10.1 Italy Antidiabetics Market, Revenues & Volume, By Product, 2019 - 2029 |
10.2 Italy Antidiabetics Market, Revenues & Volume, By Patient Population, 2019 - 2029 |
10.3 Italy Antidiabetics Market, Revenues & Volume, By Route of Administration, 2019 - 2029 |
11 Russia Antidiabetics Market, 2019 - 2029 |
11.1 Russia Antidiabetics Market, Revenues & Volume, By Product, 2019 - 2029 |
11.2 Russia Antidiabetics Market, Revenues & Volume, By Patient Population, 2019 - 2029 |
11.3 Russia Antidiabetics Market, Revenues & Volume, By Route of Administration, 2019 - 2029 |
12 Spain Antidiabetics Market, 2019 - 2029 |
12.1 Spain Antidiabetics Market, Revenues & Volume, By Product, 2019 - 2029 |
12.2 Spain Antidiabetics Market, Revenues & Volume, By Patient Population, 2019 - 2029 |
12.3 Spain Antidiabetics Market, Revenues & Volume, By Route of Administration, 2019 - 2029 |
13 Rest of Europe Antidiabetics Market, 2019 - 2029 |
13.1 Rest of Europe Antidiabetics Market, Revenues & Volume, By Product, 2019 - 2029 |
13.2 Rest of Europe Antidiabetics Market, Revenues & Volume, By Patient Population, 2019 - 2029 |
13.3 Rest of Europe Antidiabetics Market, Revenues & Volume, By Route of Administration, 2019 - 2029 |
14 Europe Antidiabetics Market Key Performance Indicators |
15 Europe Antidiabetics Market - Opportunity Assessment |
15.1 Europe Antidiabetics Market Opportunity Assessment, By Countries, 2022 & 2029F |
15.2 Europe Antidiabetics Market Opportunity Assessment, By Product, 2022 & 2029F |
15.3 Europe Antidiabetics Market Opportunity Assessment, By Patient Population, 2022 & 2029F |
15.4 Europe Antidiabetics Market Opportunity Assessment, By Route of Administration, 2022 & 2029F |
16 Europe Antidiabetics Market - Competitive Landscape |
16.1 Europe Antidiabetics Market Revenue Share, By Companies, 2022 |
16.2 Europe Antidiabetics Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Company Profiles |
18 Recommendations |
19 Disclaimer |